表紙
市場調査レポート

Argon Pharma S.L.の製品パイプライン分析

Argon Pharma S.L. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 319960
出版日 ページ情報 英文 21 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Argon Pharma S.L.の製品パイプライン分析 Argon Pharma S.L. - Product Pipeline Review - 2014
出版日: 2014年11月24日 ページ情報: 英文 21 Pages
概要

Argon Pharma S.L.はスペインに本社を置くバイオテクノロジー企業であり、腫瘍領域のアンメットニーズに対する治療薬や、新たなデリバリー技術、現存する診断技術の改良について研究開発を行っています。

当レポートでは、Argon Pharma S.L.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Argon Pharma S.L.の基本情報

  • Argon Pharma S.L.の概要
  • 主要情報
  • 企業情報

Argon Pharma S.L.:R&Dの概要

  • 主な治療範囲

Argon Pharma S.L.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Argon Pharma S.L.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Argon Pharma S.L.:薬剤プロファイル

  • APDD-01
  • APDD-04
  • SOM-0777

Argon Pharma S.L.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Argon Pharma S.L.:最新のパイプライン情報

Argon Pharma S.L.:本社と子会社の所在地

  • 本社

付録

図表一覧

目次
Product Code: GMDHC06512CDB

Summary

Global Markets Direct's, 'Argon Pharma S.L. - Product Pipeline Review - 2014', provides an overview of the Argon Pharma S.L.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Argon Pharma S.L.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Argon Pharma S.L. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Argon Pharma S.L.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Argon Pharma S.L.'s pipeline products

Reasons to buy

  • Evaluate Argon Pharma S.L.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Argon Pharma S.L. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Argon Pharma S.L.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Argon Pharma S.L. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Argon Pharma S.L.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Argon Pharma S.L. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Argon Pharma S.L. Snapshot
    • Argon Pharma S.L. Overview
    • Key Information
    • Key Facts
  • Argon Pharma S.L. - Research and Development Overview
    • Key Therapeutic Areas
  • Argon Pharma S.L. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Argon Pharma S.L. - Pipeline Products Glance
    • Argon Pharma S.L. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Argon Pharma S.L. - Drug Profiles
    • APDD-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APDD-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SOM-0777
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Argon Pharma S.L. - Pipeline Analysis
    • Argon Pharma S.L. - Pipeline Products by Target
    • Argon Pharma S.L. - Pipeline Products by Route of Administration
    • Argon Pharma S.L. - Pipeline Products by Molecule Type
    • Argon Pharma S.L. - Pipeline Products by Mechanism of Action
  • Argon Pharma S.L. - Recent Pipeline Updates
  • Argon Pharma S.L. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Argon Pharma S.L., Key Information
  • Argon Pharma S.L., Key Facts
  • Argon Pharma S.L. - Pipeline by Indication, 2014
  • Argon Pharma S.L. - Pipeline by Stage of Development, 2014
  • Argon Pharma S.L. - Monotherapy Products in Pipeline, 2014
  • Argon Pharma S.L. - Preclinical, 2014
  • Argon Pharma S.L. - Discovery, 2014
  • Argon Pharma S.L. - Pipeline by Target, 2014
  • Argon Pharma S.L. - Pipeline by Route of Administration, 2014
  • Argon Pharma S.L. - Pipeline by Molecule Type, 2014
  • Argon Pharma S.L. - Pipeline Products by Mechanism of Action, 2014
  • Argon Pharma S.L. - Recent Pipeline Updates, 2014

List of Figures

  • Argon Pharma S.L. - Pipeline by Top 10 Indication, 2014
  • Argon Pharma S.L. - Pipeline by Stage of Development, 2014
  • Argon Pharma S.L. - Monotherapy Products in Pipeline, 2014
  • Argon Pharma S.L. - Pipeline by Top 10 Molecule Type, 2014
Back to Top